Gemini Therapeutics announced it has initiated enrollment in its Phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of people in the U.S. alone. At least 90% of AMD patients have dry AMD, for which there are no approved therapies. CFH risk variants are reported to occur in greater than 40% of patients with dry AMD and are strongly associated with the risk of developing the disease. The complement system, of which CFH is a modulator, is dysregulated in patients with these risk variants and results in amplification of aberrant inflammatory responses in the eye. Over time this dysregulation leads to damage to the macular region of the retina. GEM103 is a fully functional recombinant native CFH protein intended to address dysregulation caused by loss of CFH function variants in the eyes of these AMD patients. This study is a Phase 1 single ascending dose (SAD) clinical study evaluating the safety, pharmacokinetics and pharmacodynamics of GEM103. The study targets enrolment of approximately 9 patients with dry AMD who have known CFH mutations.